Alopecia Areata Associated with Dupilumab: National Database Study

• Published in: Diagnostics (Basel) Vol. 15; no. 14; p. 1828
• Main Authors: Sontam, Tarun, Nfn, Humaira, Li, Jodi Yanking, Nadeem, Sehar, Beier, Katie, Jairath, Neil K., Ramachandran, Vignesh
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 21.07.2025; MDPI
• Subjects: adverse effect; Alopecia; alopecia areata; Atopic dermatitis; Baldness; Case reports; Cytokines; Dermatitis; Dermatology; Development and progression; Drug therapy; dupilumab; Hair loss; Inflammation; Kinases; Patients; Risk factors; Th2; United States; atopic dermatitis; adverse effect; alopecia areata; Th2; dupilumab

Background: Alopecia areata (AA), an autoimmune condition causing non-scarring hair loss, often coexists with atopic dermatitis (AD) due to shared T-helper cell type 2 (Th2)-mediated pathways. Dupilumab, a monoclonal antibody inhibiting IL-4 and IL-13 signaling, is a cornerstone treatment for AD but...